No Benefit of Saxagliptin on Cardiovascular Outcomes in Type 2 Diabetes Mellitus: Potential Explanations

被引：1
|
作者：
Jialal, Ishwarlal [1 ]
Dhindsa, Sandeep [2 ]
机构：
[1] Univ Calif Davis, Med Ctr, Lab Atherosclerosis & Metab Res, Sacramento, CA 95817 USA
[2] Texas Tech Univ, Hlth Sci Ctr, Div Endocrinol & Metab, Odessa, TX USA
来源：
METABOLIC SYNDROME AND RELATED DISORDERS | 2014年 / 12卷 / 03期
关键词：
DIPEPTIDYL PEPTIDASE-4 INHIBITORS; THERAPY;
D O I：
10.1089/met.2014.1500
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：157 / 158
页数：2
相关论文
共 50 条
  • [21] Prevention of cardiovascular outcomes in type 2 diabetes mellitus: Trials on the horizon
    Buse, JB
    Rosenstock, J
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2005, 34 (01) : 221 - +
  • [22] Risk Factors and cardiovascular Outcomes in Patients with type 2 Diabetes Mellitus
    Pavlicek, Vojtech
    DIABETOLOGE, 2018, 14 (07): : 499 - 500
  • [23] Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus
    Kulasa, Kristen
    Edelman, Steven
    CORE EVIDENCE, 2010, 5 : 23 - 37
  • [24] Sitagliptin versus saxagliptin in decompensated type 2 diabetes mellitus patients
    Asti, Antonio
    D'Alessandro, Alessandra
    Zito, Francesco Paolo
    Nardi, Salvatore
    Sarnelli, Giovanni
    Maresca, Giorgio
    D'Alessandro, Giuseppe
    ITALIAN JOURNAL OF MEDICINE, 2016, 10 (01) : 36 - 41
  • [25] SAXAGLIPTIN IN TYPE 2 DIABETES
    Billones, R.
    DRUGS OF TODAY, 2010, 46 (02) : 101 - 108
  • [26] Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials
    Nayyar Iqbal
    Artist Parker
    Robert Frederich
    Mark Donovan
    Boaz Hirshberg
    Cardiovascular Diabetology, 13
  • [27] Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials
    Iqbal, Nayyar
    Parker, Artist
    Frederich, Robert
    Donovan, Mark
    Hirshberg, Boaz
    CARDIOVASCULAR DIABETOLOGY, 2014, 13
  • [28] Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk
    Inzucchi, Silvio E.
    Wanner, Christoph
    Lachin, John M.
    Fitchett, David
    Bluhmki, Erich
    Hantel, Stefan
    Mattheus, Michaela
    Devins, Theresa
    Johansen, Odd Erik
    Woerle, Hans Juergen
    Broedl, Uli C.
    Zinman, Bernard
    CIRCULATION, 2015, 132 (23) : 2271 - 2271
  • [29] Saxagliptin for type 2 diabetes
    Chacra, Antonio R.
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2010, 3 : 325 - 335
  • [30] Know Diabetes by Heart A Partnership to Improve Cardiovascular Outcomes in Type 2 Diabetes Mellitus
    Sanchez, Eduardo J.
    Cefalu, William T.
    CIRCULATION, 2019, 140 (07) : 526 - 528
12345